News

Article

ICMRA Sets Out Recommendations on Regulation of Future Therapies Using AI

ICMRA has published a report setting out recommendations on how regulators should address the issues that the use of AI poses to global medicines regulation.

The International Coalition of Medicines Regulatory Authorities (ICMRA) has published a report setting out recommendations on how regulators should address the issues that the use of artificial intelligence (AI) poses to global medicines regulation.

To formulate the recommendations, the ICMRA Informal Network for Innovation working group employed a horizon-scanning exercise in AI and the work was led by the European Medicines Agency (EMA). Two hypothetical case studies were developed and then used to ‘stress test’ the regulatory systems of ICMRA members to see where changes may be required.

Based on the work, key issues relating to the regulation of future therapies using AI were identified and recommendations were developed by the group to foster the uptake of AI. Some of the main findings were that, when assessing and regulating AI, it may be necessary for regulators to apply a risk-based approach; strengthened governance structures should be established by stakeholders for the oversight of algorithms and AI deployments that are closely linked to the benefit/risk of a medicinal product; and that regulatory guidelines should be developed in areas such as data provenance, reliability, pharmacovigilance, and other areas.

Details from the report were published in an Aug. 16, 2021 press release from the EMA and the full report is available via ICMRA’s website. Implementation of the report is due to be discussed by ICMRA members in the coming months.

Sources: EMA, ICMRA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content